News and Announcements
Read the latest news from the Division of Hematology/Oncology including awards, publications and announcements.
Twelve Feinberg faculty members were named to the 2023 “Highly Cited Researchers” list, published by Clarivate Analytics. The annual list identifies investigators who have demonstrated significant influence in their field through the publication of highly cited publications during the last decade.
Northwestern investigators, clinicians, and people living with ALS convened in the Feinberg Pavilion for the 13th annual Les Turner Symposium on ALS to celebrate and share new scientific breakthroughs that improve the understanding of ALS and advancements in treating the disease.
Investigators led by Neil Kelleher, PhD, have developed an automated technique for imaging proteoforms in ovarian cancer, according to results published in Nature Communications.
Northwestern Medicine scientists have developed a more effective way of creating nanotherapeutic vaccines and medicines, according to a study published in ACS Nano.
Combining immunotherapy with radiation may be a promising treatment option for patients with advanced soft tissue sarcoma, according to the results of a Northwestern Medicine clinical trial published in JAMA Oncology.
In 2022, Feinberg established research into social determinants of health as a priority. To better understand the impact of social determinants of health, Feinberg investigators have been leading studies that provide new insights into how a person’s neighborhood can positively or negatively affect their health.
A combination immunotherapy treatment of nivolumab plus ipilimumab was associated with no improvement in survival for advanced cancers other than melanoma, when compared to nivolumab alone, according to a recent Northwestern Medicine meta-analysis published in JAMA Oncology.
David Cella, PhD, professor of Medical Social Sciences, has been named the winner of the 2023 Tripartite Legacy Faculty Prize in Translational Science and Education.
Brian Lee, a second-year student in the Medical Scientist Training Program (MSTP), was the lead author of a study that found that a new combination therapy regimen improved survival in patients with B-cell lymphoma by 30 percent.
Combining immunotherapy with a tumor-targeted virus may help extend survival in some patients with recurrent glioblastoma, according to the results of a trial published in Nature Medicine.
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University has received a renewed five-year $10.8 million Specialized Program of Research Excellence (SPORE) grant from the National Cancer Institute for the Lurie Cancer Center to advance translational research and improve outcomes for patients with brain cancer.
Black residents living in highly segregated neighborhoods have significantly shortened life expectancies, according to a new Northwestern Medicine study.
A single infusion of CAR T-cell therapy induced complete response or remission in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to a recent clinical trial published in The Lancet.
Adding a checkpoint inhibitor to conventional chemotherapy improved outcomes for patients with relapsed or refractory classic Hodgkin lymphoma, according to a Northwestern Medicine phase II clinical trial published in JAMA Oncology.
Northwestern Medicine investigators have discovered novel features of circulating tumor stem cells that can promote chemotherapy evasion and metastasis in triple-negative breast cancer, according to a recent study.
Northwestern investigators have demonstrated that fine-tuning DNA interaction strength can improve colloidal crystal engineering to enhance their use in creating an array of functional nanomaterials.
Five Feinberg faculty members have been inducted into the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP), two of the oldest medical honor societies in the U.S.
A combination treatment approach using two chemotherapy drugs improved treatment response and progression-free survival in patients with advanced pancreatic neuroendocrine tumors, according to a recent clinical trial published in the Journal of Clinical Oncology.
Patients with advanced-stage melanoma who received immunotherapy both before and after surgery had longer event-free survival than patients who received immunotherapy only after surgery, according to a recent clinical trial published in the New England Journal of Medicine.
Combining a new hormone therapy drug with chemotherapy and another hormone therapy increased overall survival in patients with high-volume and both high-risk and low-risk metastatic hormone-sensitive prostate cancer, according to a post hoc analysis published in the Journal of Clinical Oncology.
A new way to significantly increase the potency of almost any vaccine has been developed by Northwestern scientists.
Targeting cellular post-transcription mechanisms in the CD73 ectoenzyme may promote anti-tumor immunity and slow cancer progression in triple-negative breast cancer, according to a recent Northwestern Medicine study.
Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood.
Patient-reported outcomes in relapsed or refractory large B-cell lymphoma revealed that receiving CAR T-cell immunotherapy was associated with higher quality of life, according to a recent study.
A Northwestern Medicine study has discovered that elevated PALI1 in advanced prostate tumors mediates crosstalk between two primary epigenetic silencing mechanisms, suggesting that dual epigenetic inhibition may be an effective therapeutic strategy.
Investigators have developed a novel personalized T-cell therapy approach that may identify specific targets unique to a patient’s cancer cells more effectively than current treatments, according to findings published in Nature.
Northwestern Medicine scientists have identified a new therapeutic target against tumor cells and developed a compound which slows tumor growth and bolsters immune response.
Twelve faculty with appointments at Feinberg were named to the 2022 “Highly Cited Researchers” list, published by Clarivate Analytics.
Northwestern Medicine investigators have discovered the mechanisms by which a particular protein promotes cancer cell proliferation and survival in acute myeloid leukemia, according to findings published in Blood.